Stock listing
NASDAQ:RLYB Rallybio Corporation Stock
Home listing (NASDAQ) of Rallybio Corporation
Follow Rallybio Corporation into a list and get an email when it puts out news.
Share price · NASDAQ:RLYB
$15.47 USD +0.21 (+1.4%)
Close on Nov 20, 2026
- Day range
- $15.15 – $15.70 USDNov 20, 2026
- Volume
- 50,485 sharesNov 20, 2026
- Market cap
- $83.29M USDAt the close on Nov 20, 2026 · price × 5.38M shares outstanding
- 52-week range
- $3.67 – $17.57 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $311,369 USDMedian day 8,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RLYB · Home | $15.47 USD | +0.21 (+1.4%) | 50,485 | $15.32 | $15.70 | $15.15 | $15.26 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RLYB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $15.47 | +0.21 | +1.4% | $15.32 | $15.70 | $15.15 | 50,485 | |
| $15.26 | -0.03 | -0.2% | $15.29 | $15.37 | $15.05 | 28,765 | |
| $15.29 | -0.135 | -0.9% | $15.35 | $15.37 | $15.07 | 44,032 | |
| $15.43 | -0.295 | -1.9% | $15.79 | $15.98 | $15.09 | 44,476 | |
| $15.72 | +0.07 | +0.4% | $15.62 | $15.79 | $15.50 | 10,932 | |
| $15.65 | -0.15 | -0.9% | $15.89 | $15.89 | $15.51 | 23,314 | |
| $15.80 | +0.04 | +0.3% | $15.86 | $15.86 | $15.50 | 44,474 | |
| $15.76 | +0.10 | +0.6% | $15.66 | $15.76 | $15.32 | 25,130 | |
| $15.66 | -0.09 | -0.6% | $15.53 | $16.00 | $15.53 | 25,930 | |
| $15.75 | +0.06 | +0.4% | $15.73 | $15.85 | $15.51 | 53,302 | |
| $15.69 | -0.21 | -1.3% | $15.71 | $15.87 | $15.59 | 21,861 | |
| $15.90 | +0.04 | +0.3% | $16.07 | $16.17 | $15.45 | 59,434 | |
| $15.86 | +0.10 | +0.6% | $15.76 | $16.43 | $15.50 | 45,759 | |
| $15.76 | +0.22 | +1.4% | $15.91 | $16.23 | $15.55 | 59,403 | |
| $15.54 | +0.13 | +0.8% | $15.42 | $16.25 | $15.30 | 61,712 | |
| $15.41 | -0.58 | -3.6% | $15.88 | $16.28 | $15.28 | 51,893 | |
| $15.99 | +0.06 | +0.4% | $15.66 | $16.44 | $15.66 | 22,375 | |
| $15.93 | -0.72 | -4.3% | $16.46 | $16.46 | $15.51 | 52,617 | |
| $16.65 | +0.01 | +0.1% | $16.71 | $16.71 | $16.50 | 3,538 | |
| $16.64 | +0.24 | +1.5% | $16.62 | $16.79 | $16.40 | 6,200 | |
| $16.40 | +0.18 | +1.1% | $16.20 | $16.41 | $16.20 | 5,500 | |
| $16.22 | -0.16 | -1.0% | $16.37 | $16.62 | $16.16 | 13,600 | |
| $16.38 | +0.03 | +0.2% | $16.48 | $16.48 | $16.36 | 102,600 | |
| $16.35 | +0.07 | +0.4% | $16.40 | $16.43 | $16.20 | 8,100 | |
| $16.28 | -0.495 | -3.0% | $16.70 | $16.70 | $16.20 | 37,100 | |
| $16.78 | -0.13 | -0.8% | $16.88 | $16.88 | $16.62 | 3,200 | |
| $16.91 | +0.185 | +1.1% | $16.79 | $16.91 | $16.74 | 5,300 | |
| $16.72 | -0.07 | -0.4% | $16.72 | $16.91 | $16.69 | 5,200 | |
| $16.79 | -0.23 | -1.4% | $16.88 | $17.08 | $16.75 | 6,000 | |
| $17.02 | +0.03 | +0.2% | $17.05 | $17.22 | $16.95 | 6,900 | |
| $16.99 | +0.06 | +0.4% | $16.75 | $17.04 | $16.75 | 7,900 | |
| $16.93 | -0.15 | -0.9% | $16.91 | $17.04 | $16.80 | 7,500 | |
| $17.08 | +0.18 | +1.1% | $16.87 | $17.08 | $16.80 | 1,900 | |
| $16.90 | -0.18 | -1.1% | $16.99 | $17.12 | $16.82 | 4,600 | |
| $17.08 | +0.32 | +1.9% | $16.69 | $17.22 | $16.69 | 7,900 | |
| $16.76 | -0.44 | -2.6% | $17.16 | $17.16 | $16.76 | 7,100 | |
| $17.20 | -0.02 | -0.1% | $17.24 | $17.24 | $16.93 | 6,000 | |
| $17.22 | +0.17 | +1.0% | $16.90 | $17.24 | $16.61 | 16,700 | |
| $17.05 | +0.43 | +2.6% | $16.55 | $17.05 | $16.55 | 16,100 | |
| $16.62 | +0.01 | +0.1% | $16.80 | $17.07 | $16.62 | 7,000 | |
| $16.61 | -0.25 | -1.5% | $16.74 | $16.75 | $16.61 | 6,800 | |
| $16.86 | -0.06 | -0.4% | $16.66 | $16.86 | $16.61 | 5,300 | |
| $16.92 | -0.01 | -0.1% | $16.85 | $17.11 | $16.72 | 7,600 | |
| $16.93 | -0.26 | -1.5% | $17.14 | $17.14 | $16.61 | 7,900 | |
| $17.19 | +0.03 | +0.2% | $17.16 | $17.20 | $16.92 | 16,100 | |
| $17.16 | +0.07 | +0.4% | $17.18 | $17.18 | $17.13 | 4,300 | |
| $17.09 | -0.13 | -0.8% | $17.24 | $17.24 | $16.71 | 17,800 | |
| $17.22 | +0.71 | +4.3% | $16.49 | $17.22 | $16.45 | 22,200 | |
| $16.51 | -0.365 | -2.2% | $16.98 | $16.98 | $16.50 | 14,300 | |
| $16.88 | +0.125 | +0.7% | $16.75 | $16.88 | $16.70 | 6,600 | |
| $16.75 | -0.22 | -1.3% | $16.80 | $17.06 | $16.71 | 6,100 | |
| $16.97 | +0.36 | +2.2% | $16.52 | $17.05 | $16.50 | 9,000 | |
| $16.61 | -0.315 | -1.9% | $16.97 | $16.97 | $16.61 | 7,000 | |
| $16.93 | +0.05 | +0.3% | $16.75 | $17.01 | $16.75 | 4,200 | |
| $16.88 | -0.065 | -0.4% | $16.66 | $17.09 | $16.66 | 2,500 | |
| $16.94 | +0.25 | +1.5% | $16.65 | $17.26 | $16.65 | 29,800 | |
| $16.69 | -0.10 | -0.6% | $17.05 | $17.05 | $16.67 | 11,200 | |
| $16.79 | -0.02 | -0.1% | $16.68 | $17.05 | $16.50 | 14,100 | |
| $16.81 | +0.05 | +0.3% | $16.51 | $17.12 | $16.51 | 5,800 | |
| $16.76 | -0.12 | -0.7% | $17.18 | $17.23 | $16.76 | 5,900 | |
| $16.88 | -0.005 | 0.0% | $16.95 | $17.03 | $16.75 | 3,700 | |
| $16.89 | +0.085 | +0.5% | $16.81 | $17.03 | $16.64 | 7,444 | |
| $16.80 | -0.03 | -0.2% | $16.54 | $16.86 | $16.54 | 6,681 | |
| $16.83 | +0.23 | +1.4% | $16.76 | $16.95 | $16.55 | 6,900 | |
| $16.60 | -0.40 | -2.4% | $16.78 | $16.98 | $16.51 | 15,300 |
Splits
1 split · NASDAQ:RLYB · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-8 | Consolidation |
- Ticker
- NASDAQ:RLYB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 11, 2026
Correction to Press Release Announcing Reverse Stock Split of Rallybio Common Stock in Connection with the Proposed Merger with Avenzo
Latest deck · Jun 1, 2026
Merger or Acquisition (June 2026)
Merger or acquisition · 30 slides
Latest news
Correction to Press Release Announcing Reverse Stock Split of Rallybio Common Stock in Connection with the Proposed Merger with Avenzo
Nov 11, 2026
Closed $15.80 (+0.3%) on Nov 11, 2026
Rallybio Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with Avenzo
Nov 10, 2026
Closed $15.80 (+0.3%) on Nov 11, 2026
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
Jun 1, 2026
Closed $16.87 (+16.7%) on Jun 1, 2026
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
Mar 2, 2026
Closed $10.97 (+45.5%) on Mar 2, 2026
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
Feb 17, 2026
Closed $4.33 (-10.2%) on Feb 17, 2026
Rallybio Announces Reverse Stock Split of Common Stock
Feb 3, 2026
Closed $4.60 (-8.1%) on Feb 4, 2026
Rallybio Corporation on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 6 in the last 12 months · 91 in all · newest Nov 11, 2026 · oldest 2021
- Decks
- 5 decks · latest Jun 1, 2026
Where Rallybio Corporation is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RLYB · Home listing · This page | NASDAQ | United States | USD |
| BOATS:RLYB | BOATS | United States | USD |
Valuation
EV/sales −17.1× against a median of 25.1×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$7.40M USD
- P/E
- 3.1×
- EV/sales
- −17.1×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.9×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.58
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Rallybio Corporation · NASDAQ:RLYB | US$83.29M | −US$7.40M | 3.1× | −17.1× | n/a | 0.9× | n/a | 0.0× | 0.58 |
| Formosa Pharmaceuticals, Inc. · TWSE:6838 | US$85.43M | US$48.52M | n/a | 30.4× | n/a | 2.0× | −361.4% | 0.0× | n/a |
| Genome & Co. · KRX:314130 | US$85.27M | US$37.21M | n/a | 2.0× | n/a | 1.6× | −169.1% | 0.0× | n/a |
| Anixa Biosciences, Inc. · NASDAQ:ANIX | US$84.82M | US$70.96M | n/a | n/a | n/a | 5.9× | n/a | 0.0× | 1.45 |
| BetterLife Pharma Inc. · CSE:BETR | US$84.03M | US$83.37M | n/a | n/a | n/a | n/a | n/a | n/a | 1.14 |
| Shine-On Biomedical Co., Ltd. · TPEX:6926 | US$83.56M | US$59.02M | n/a | 64.8× | n/a | 3.5× | −367.6% | 0.0× | n/a |
| TuHURA Biosciences, Inc. · NASDAQ:HURA | US$82.20M | US$89.50M | n/a | n/a | n/a | 4.3× | n/a | 0.5× | 2.81 |
| 3D Medicines, Inc. · HKEX:1244 | US$81.88M | US$48.45M | n/a | 0.9× | n/a | 1.0× | −49.9% | 0.3× | n/a |
| Kintor Pharmaceutical Ltd · HKEX:9939 | US$81.70M | US$96.94M | n/a | 19.8× | n/a | 5.0× | −612.3% | 1.2× | n/a |
| Nkarta, Inc. · NASDAQ:NKTX | US$81.38M | −US$75.22M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.67 |
| Captor Therapeutics SA · GPW:CTX | US$81.11M | US$64.15M | n/a | 130× | n/a | 5.1× | n/a | 0.0× | n/a |
| Median of the others | US$82.88M | US$61.59M | 25.1× | 3.5× | −361.4% | 0.0× | 1.56 |
Forecasts
Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -5.52 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Steve Uden | Co-Founder and Chief Executive Officer |
| Jonathan I. Lieber | Chief Financial Officer |
| Hui Liu | Executive Vice President, Chief Business Officer and Head of US |
| Amanda Hayward | Executive Chairman of Hoba Therapeutics |
| Martin Mackay | Co-Founder and Chairman |
Board
| Director | Role |
|---|---|
| Christine A. Nash | Board Chair |
| Martin Mackay | Co-Founder and Chairman |
| Helen M. Boudreau | Board Member |
| Lucian Iancovici | Board Member |
| Paula Soteropoulos | Lead Independent Director |
| Rob Hopfner | Board Member |
| Ron Hunt | Board Member |
| Wendy K. Chung | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 27, 2026 | −4.0% |
| Q2 2026 | Aug 6, 2026 · Before open | +0.3% |
| Q1 2026 | May 13, 2026 · After close | −1.0% |
| Q4 2025 | Mar 17, 2026 | −0.5% |
| Q3 2025 | Nov 6, 2025 · Before open | +2.2% |
| Q2 2025 | Aug 7, 2025 · Before open | −3.2% |
| Q1 2025 | May 8, 2025 · Before open | −2.5% |
| Q4 2024 | Mar 13, 2025 | −4.1% |
| Q3 2024 | Nov 7, 2024 · Before open | −1.0% |
| Q2 2024 | Aug 8, 2024 · Before open | −0.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | +2.7% |
| Q4 2023 | Mar 12, 2024 · Before open | −8.7% |
| Q3 2023 | Nov 9, 2023 · Before open | +1.3% |
| Q2 2023 | Aug 8, 2023 · Before open | −4.0% |
| Q1 2023 | May 9, 2023 · Before open | −7.0% |
| Q4 2022 | Mar 6, 2023 · Before open | +10.3% |
| Q3 2022 | Nov 7, 2022 · Before open | +4.1% |
| Q2 2022 | Aug 8, 2022 · Before open | −5.8% |
| Q1 2022 | May 10, 2022 · Before open | +6.0% |
| Q4 2021 | Mar 15, 2022 · Before open | −10.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (June 2026) | Merger or acquisition | 30 slides | Jun 1, 2026 |
| Merger or Acquisition (March 2026) | Merger or acquisition | 36 slides | Mar 2, 2026 |
| Corporate Update (December 2023) | Corporate update | 6 slides | Dec 20, 2023 |
| 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2023 | Conference | 14 slides | Jun 24, 2023 |
| Investor Presentation (March 2022) | Investor deck | 29 slides | Mar 7, 2022 |
IPO
Priced at US$13.00 a share on Jul 28, 2021.
- Price
- US$13.00 a share
- Shares offered
- 6,200,000 shares of common stock
- Offering size
- US$80.6 million
- Underwriters' option
- Up to 930,000 more shares
- Underwriters
- Jefferies, Cowen, Evercore ISI · In the order on the cover
- Shares delivered
- On or about Aug 2, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 27, 2021 |
| Filed publicly | Jul 2, 2021 |
| Amended once | Jul 22, 2021 |
| Declared effective by the SEC | Jul 28, 2021 |
| Shares registered with an exchange | Jul 29, 2021 |
| Final prospectus, with the price | Jul 30, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 30, 2021 |
| CERT · Exchange's certificate of listing | Jul 29, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 29, 2021 |
| EFFECT · Notice that a registration is effective | Jul 28, 2021 |
| S-1MEF · Registration of more shares for the same offering | Jul 28, 2021 |
| CORRESP · Letter to the SEC | Jul 26, 2021 |
| CORRESP · Letter to the SEC | Jul 26, 2021 |
| S-1/A · Registration statement, amended | Jul 22, 2021 |
| CORRESP · Letter to the SEC | Jul 12, 2021 |
| S-1 · Registration statement | Jul 2, 2021 |
All 14 filings
| Filing | Filed |
|---|---|
| DRSLTR · Letter to the SEC with a draft | Jun 7, 2021 |
| DRS/A · Draft registration statement, amended | Jun 7, 2021 |
| UPLOAD · Letter from the SEC | May 24, 2021 |
| DRS · Draft registration statement | Apr 27, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 30, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 858.0K | 636.0K | ||||
| Research and development | 19.6M | 41.5M | 53.5M | 40.7M | 26.9M | 17.6M |
| Operating income | -33.1M | -60.5M | -78.9M | -67.9M | -45.6M | -25.3M |
| Depreciation and amortization | 92.0K | 131.0K | 150.0K | 167.0K | 109.0K | 62.0K |
| EBITDA | -33.0M | -60.4M | -78.8M | -67.7M | -45.5M | -25.2M |
| Interest expense | 0 | 10.0K | 49.0K | |||
| Income before tax | -8.98M | -55.5M | -72.5M | -65.6M | -45.5M | -24.9M |
| Income tax | 0 | 0 | 0 | 0 | 0 | -15.0K |
| Net income | -8.98M | -57.8M | -74.6M | -66.7M | -47.0M | -26.4M |
| Earnings per share, basic | -1.59 | -10.61 | -1.84 | -2.09 | -1.84 | -1.52 |
| Earnings per share, diluted | -1.59 | -10.61 | -1.84 | -2.09 | -1.84 | -1.52 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 31.4M | 13.9M | 24.5M | 57.0M | 175.3M | 140.2M |
| Short-term investments | 23.4M | 51.6M | 85.4M | 112.0M | 0 | |
| Current assets | 61.3M | 67.8M | 114.8M | 179.5M | 180.9M | 141.3M |
| Property, plant and equipment | 23.0K | 115.0K | 246.0K | 385.0K | 511.0K | 287.0K |
| Total assets | 62.3M | 68.1M | 115.6M | 180.4M | 182.2M | 141.9M |
| Accounts payable | 126.0K | 278.0K | 976.0K | 1.11M | 603.0K | 1.58M |
| Current liabilities | 4.22M | 6.24M | 9.26M | 10.7M | 6.55M | 5.84M |
| Total liabilities | 4.30M | 6.45M | 9.44M | 11.1M | 6.58M | 5.86M |
| Shareholders' equity | 58.0M | 61.7M | 106.2M | 169.3M | 175.6M | 136.0M |
| Shares outstanding | 5.28M | 5.19M | 37.8M | 37.8M | 32.1M | 23.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -29.8M | -49.3M | -60.3M | -57.3M | -45.5M | -22.0M |
| Capital spending | 0 | -12.0K | -54.0K | -333.0K | -137.0K | |
| Free cash flow | -49.3M | -60.3M | -57.3M | -45.9M | -22.2M | |
| Cash from investing | 47.3M | 33.5M | 27.7M | -112.2M | -2.33M | -2.07M |
| Cash from financing | 16.0K | 5.20M | 143.0K | 51.1M | 83.0M | 144.9M |
| Change in cash | 17.5M | -10.6M | -32.5M | -118.4M | 35.1M | 120.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 425 | Nov 12, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 12, 2026 | Current report | SEC |
| 425 | Nov 10, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 10, 2026 | Current report | SEC |
| 425 | Nov 6, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 6, 2026 | Current report | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 4, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Oct 27, 2026 | Quarterly report | SEC |
| 425 | Oct 26, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 26, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Oct 16, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Oct 15, 2026 | Offer document | SEC |
| S-4/A · Registration statement, amended | Oct 14, 2026 | Offer document | SEC |
| 4 · Change in ownership | Oct 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2026 | Insider trade | SEC |
| S-4/A · Registration statement, amended | Oct 2, 2026 | Offer document | SEC |
| 4 · Change in ownership | Oct 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| S-4/A · Registration statement, amended | Sep 15, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 9, 2026 | Management or board change | SEC |
| S-4/A · Registration statement, amended | Aug 26, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 4, 2026 | Big-stake notice | SEC |
| S-4 · Registration statement | Jul 15, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 5, 2026 | Big-stake notice | SEC |
| 425 | Jun 1, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 1, 2026 | Material contract | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 6, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 6, 2026 | Big-stake notice | SEC |
| RW · Request to withdraw a registration | May 5, 2026 | Other filings | SEC |
| 8-K · Current report | May 4, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| S-4/A · Registration statement, amended | Apr 24, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 31, 2026 | Management or board change | SEC |
| S-4 · Registration statement | Mar 16, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 16, 2026 | Annual report | SEC |
| 3 · Initial statement of ownership | Mar 10, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 3, 2026 | Big-stake notice | SEC |
| 425 | Mar 2, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 2, 2026 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 29, 2026 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Jan 2, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Dec 23, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 8-K · Current report | Aug 29, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 8-K · Current report | Jul 8, 2025 | Acquisition or disposal | SEC |
| 8-K · Current report | Jun 27, 2025 | Management or board change | SEC |
| 8-K · Current report | May 16, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 9, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 8-K · Current report | Apr 8, 2025 | Current report | SEC |
| DEF 14A · Proxy statement | Apr 7, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 13, 2025 | Current report | SEC |
| 424B5 · Prospectus | Mar 13, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 13, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 13, 2025 | Results | SEC |
| 8-K · Current report | Feb 25, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 8-K · Current report | Sep 17, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Jul 30, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 30, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jul 23, 2024 | Management or board change | SEC |
| 8-K · Current report | May 21, 2024 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | May 21, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2024 | Insider trade | SEC |
| CORRESP · Letter to the SEC | May 16, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 16, 2024 | Other filings | SEC |
| S-3 · Registration statement | May 10, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| D | Apr 22, 2024 | Other filings | SEC |
| DEF 14A · Proxy statement | Apr 11, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 10, 2024 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Mar 13, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 12, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2024 | Results | SEC |
| 4 · Change in ownership | Feb 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 16, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 6, 2024 | Results | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 2, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Dec 20, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2023 | Results | SEC |
| 8-K · Current report | Jun 29, 2023 | Management or board change | SEC |
| 8-K · Current report | May 22, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | May 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2023 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | May 15, 2023 | Other filings | SEC |
| 424B3 · Prospectus | May 12, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 11, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 11, 2023 | Other filings | SEC |
| S-8 · Registration statement for employee plans | May 10, 2023 | Offer document | SEC |
| S-3 · Registration statement | May 9, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | May 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2023 | Results | SEC |
| DEF 14A · Proxy statement | Apr 10, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2023 | Insider trade | SEC |
| 10-K · Annual report | Mar 6, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2023 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 6, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 1, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 1, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 1, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jan 31, 2023 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 23, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 1, 2022 | Current report | SEC |
| 4 · Change in ownership | Nov 17, 2022 | Insider trade | SEC |
| SC 13G · Big-stake notice | Nov 17, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Nov 14, 2022 | Material contract | SEC |
This page holds 200 of 314 filings. Open Filings
Cap table
Built by 6ix from Rallybio Corporation’s releases
- Common shares
- 5,383,937
- Fully diluted
- 5,383,937
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 5,383,937 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 5,383,937 |
| Nov 11, 2026 | |
| Nov 10, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Martin Mackay Other companies: Kailera Therapeutics, Inc. (Director · Since at least Apr 16, 2026); SpringWorks Therapeutics Inc (Director · Since at least Jul 29, 2024); Charles River Laboratories International, Inc. (Director · Since at least Jul 1, 2017); 5 01 Acquisition Corp (Director · Oct 13, 2020 – Oct 16, 2020 · Past); Alexion Pharmaceuticals Inc (EVP & Global Head of R&D · May 13, 2013 – Feb 27, 2017 · Past); Pfizer, Inc. (Senior Vice President · Sep 30, 2008 – May 14, 2010 · Past) | Director · Since at least Jul 28, 2021 |
| Helen M. Boudreau Other companies: Shattuck Labs, Inc. (Director · Since at least Oct 8, 2020); Tvardi Therapeutics, Inc. (Director · Aug 2, 2023 – Jun 4, 2024 · Past); Kineta Inc. (Chief Financial Officer · Feb 10, 2016 – Mar 1, 2018 · Past) | Board Member · Since at least Jul 29, 2021 |
| Jonathan I. Lieber Other companies: Decoy Therapeutics Inc. (Director · Since at least Jun 7, 2022) | Chief Financial Officer · Since at least Feb 1, 2023 |
| Paula Soteropoulos Other companies: Dianthus Therapeutics, Inc. (Director · Since at least May 22, 2025) | Lead Independent Director · Since at least May 13, 2025 |
| Wendy Chung Other companies: Prime Medicine, Inc. (Board Member · Since at least Oct 19, 2022) | Board Member · Since at least Aug 1, 2022 |
| Amanda Hayward | Executive Chairman of Hoba Therapeutics · Since at least Nov 4, 2026 |
| Christine A. Nash | Director · Since at least Apr 4, 2022 |
| David Bejker | CEO · Jun 13, 2025 – Nov 4, 2026 · Past |
| Hui Liu | Executive Vice President, Chief Business Officer and Head of US · Since at least Sep 24, 2026 |
| Lucian Iancovici | Board Member · Since at least Nov 5, 2026 |
All 18 people
| Person | Seat |
|---|---|
| Martin Mackay | Co-Founder and Chairman · Since at least Nov 5, 2026 |
| Peter Zerhouni | CFO and CBO · Jun 13, 2025 – Nov 4, 2026 · Past |
| Robert Lorne Hopfner | Director · Since at least Oct 12, 2026 |
| Rob Hopfner | Board Member · Since at least Oct 14, 2026 |
| Ronald Hunt | Director · Since at least Oct 29, 2026 |
| Ron Hunt | Board Member · Since at least Nov 2, 2026 |
| Stephen Uden | Chief Executive Officer, Director · Since at least Jul 28, 2021 |
| Steve Uden | Co-Founder and Chief Executive Officer · Since at least Oct 29, 2026 |
Log in to ask 6ix AI your own questions about Rallybio Corporation.